Delafloxacin Pharmacokinetics in Subjects With Varying Degrees of Renal Function
Open Access
- 18 December 2017
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 58 (4), 514-521
- https://doi.org/10.1002/jcph.1041
Abstract
Delafloxacin, a fluoroquinolone, has activity against gram-positive organisms including methicillin-resistant Staphylococcus aureus and fluoroquinolone-susceptible and –resistant gram-negative organisms. This study was conducted to determine delafloxacin pharmacokinetics after a single intravenous infusion or oral dose administration in subjects with varying degrees of renal function. The study was an open-label, parallel-group crossover study in subjects with normal renal function or with mild, moderate, or severe renal impairment. Subjects received 300 mg delafloxacin intravenously, placebo intravenously, and 400 mg delafloxacin orally in 3 periods separated by ≥14-day washouts. Blood and urine pharmacokinetic parameters were calculated using noncompartmental methods. Delafloxacin total clearance decreased with decreasing renal function, with a corresponding increase in AUC0–∞. After intravenous administration, mean total clearance was 13.7 and 7.07 L/h, and mean AUC0–∞ was 22.6 and 45.0 μg·h/mL in normal and severe renal subjects, respectively. Mean renal clearance as determined by urinary excretion was 6.03 and 0.44 L/h in normal and severe renal impairment subjects, respectively. Total clearance exhibited linear relationships to eGFR and CLCR. Similar observations were found after oral administration of delafloxacin. Single doses of delafloxacin 300 mg intravenously and 400 mg orally were well tolerated in all groups. In conclusion, renal insufficiency has an effect on delafloxacin clearance; a dosing adjustment for intravenous dosing is warranted for patients with severe renal impairment (eGFR < 30 mL/min).Keywords
Funding Information
- Melinta Therapeutics, Inc
This publication has 13 references indexed in Scilit:
- Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy VolunteersClinical Therapeutics, 2016
- Single and Multiple Ascending-dose Studies of Oral Delafloxacin: Effects of Food, Sex, and AgeClinical Therapeutics, 2016
- Evolving Resistance Among Gram-positive PathogensClinical Infectious Diseases, 2015
- Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacyFuture Microbiology, 2015
- Disposition, metabolism and mass balance of delafloxacin in healthy human volunteers following intravenous administrationXenobiotica, 2015
- Novel antibiotics: Are we still in the pre–post-antibiotic era?Infection, 2015
- White Paper: Recommendations on the Conduct of Superiority and Organism-Specific Clinical Trials of Antibacterial Agents for the Treatment of Infections Caused by Drug-Resistant Bacterial PathogensClinical Infectious Diseases, 2012
- Does the Dose Matter?Clinical Infectious Diseases, 2001
- A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction EquationAnnals of Internal Medicine, 1999
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976